Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novacyt ( (FR:ALNOV) ) has provided an update.
Novacyt S.A. reported its full-year 2024 results, showcasing a significant 85% year-on-year revenue growth, driven by the acquisition of Yourgene. The company achieved a gross profit margin of 163%, largely due to a one-time reversal of a product warranty provision. Operational highlights included the successful integration of Yourgene, site consolidations, and new product launches, positioning Novacyt for future growth. The company remains focused on cost reductions and strategic investments in R&D to enhance its product offerings, aiming for EBITDA profitability.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation for human health, animal health, and environmental sectors. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, with a significant presence in over 65 countries.
YTD Price Performance: -15.00%
Average Trading Volume: 150
Technical Sentiment Signal: Buy
Current Market Cap: $36.93M
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.